Medicare Enrolled
Dr. James Boehmke, D.O.
Gastroenterology · Texarkana, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Boehmke from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Boehmke?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Boehmke
Dr. James Boehmke is a gastroenterology specialist in Texarkana, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Boehmke performed 8,686 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Boehmke received a total of $12,960 from 49 pharmaceutical and/or device companies across 913 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Boehmke is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 1% volume in TX
$12,960 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗8,686
Medicare services
Top 1% in TX for gastroenterology
Not available
Unique patients (not deduplicated)
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Vedolizumab infusion (Entyvio) This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams. |
6,900 | $17 | $50 |
| Chronic care management, additional 20 min/month This service covers an extra 20 minutes of clinical staff time directed by a healthcare professional for managing two or more chronic conditions each calendar month. |
470 | $37 | $92 |
| Chronic care management, first 20 min/month This service covers the first 20 minutes of clinical staff time directed by a healthcare professional each calendar month to manage chronic conditions. |
289 | $49 | $122 |
| Colon polyp removal with endoscopic snare This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination. |
183 | $192 | $1,017 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
99 | $79 | $184 |
| Upper GI endoscopy with biopsy A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities. |
96 | $49 | $700 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
87 | $60 | $120 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
72 | $116 | $261 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
59 | $60 | $109 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
52 | $86 | $156 |
| Remote patient monitoring management, 20 min/month Management based on results from remote vital sign monitoring for the first 20 minutes per calendar month. |
49 | $38 | $94 |
| Esophageal dilation with guide wire and endoscope A flexible endoscope is used to insert a guide wire into the esophagus, followed by dilation to widen the esophageal passage. |
48 | $114 | $750 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
43 | $102 | $220 |
| Remote patient monitoring device, 30 days Initial setup of devices for remote monitoring of body functions with daily data transmission or alerts. This service covers the first 30 days of the monitoring period. |
39 | $38 | $95 |
| Colonoscopy with biopsy A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease. |
29 | $92 | $804 |
| Colonoscopy for colorectal cancer screening A colonoscopy performed to screen for colorectal cancer in individuals who are not at high risk for the disease. |
26 | $168 | $723 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
22 | $48 | $172 |
| Colonoscopy A diagnostic exam of the large bowel using a flexible endoscope to visualize the interior of the colon. |
21 | $129 | $723 |
| Upper endoscopy (EGD) A diagnostic exam of the esophagus, stomach, and upper small bowel using a flexible endoscope. |
20 | $69 | $547 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
20 | $37 | $74 |
| Liver stiffness measurement A non-invasive test that uses ultrasound or similar technology to measure the stiffness of liver tissue. This measurement helps assess the degree of liver fibrosis or scarring. |
16 | $8 | $125 |
| Colonoscopy for colorectal cancer screening, high risk A colonoscopy performed to screen for colorectal cancer in individuals identified as being at high risk for the disease. |
16 | $178 | $1,559 |
| Injection beneath large bowel lining via endoscope A flexible endoscope is used to inject medication or fluid beneath the lining of the large intestine. |
15 | $15 | $678 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
15 | $134 | $306 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
79.7% high complexity
2.6% medium
17.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$12,960
Total received (2018-2024)
Avg $1,851/year across 7 years
Top 16% in TX for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
49
Companies
913
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,296
2023
$2,095
2022
$2,156
2021
$2,261
2020
$1,320
2019
$1,615
2018
$1,217
Payments by company (2024)
ABBVIE INC.
$695
Takeda Pharmaceuticals U.S.A., Inc.
$389
Janssen Biotech, Inc.
$232
Lilly USA, LLC
$153
GENZYME CORPORATION
$140
PFIZER INC.
$135
Ardelyx, Inc.
$90
Phathom Pharmaceuticals, Inc.
$80
Merck Sharp & Dohme LLC
$75
Gilead Sciences, Inc.
$65
Madrigal Pharmaceuticals
$50
Celgene Corporation
$50
Intercept Pharmaceuticals, Inc.
$32
AstraZeneca Pharmaceuticals LP
$29
Enterra Medical, Inc.
$22
Ferring Pharmaceuticals Inc.
$21
AIMMUNE THERAPEUTICS, INC.
$19
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$17
Top 3 companies account for 57.3% of 2024 payments
All-time payments by company (2018-2024) ›
Takeda Pharmaceuticals U.S.A., Inc.
$1,895
AbbVie Inc.
$1,558
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$1,417
ABBVIE INC.
$1,224
Gilead Sciences, Inc.
$1,070
Janssen Biotech, Inc.
$870
PFIZER INC.
$814
AbbVie, Inc.
$707
GENZYME CORPORATION
$362
Braintree Laboratories, Inc.
$286
Ardelyx, Inc.
$280
INTERCEPT PHARMACEUTICALS, INC.
$219
UCB, Inc.
$180
Allergan Inc.
$173
Lilly USA, LLC
$153
Merck Sharp & Dohme LLC
$151
Evoke Pharma, Inc.
$138
Ferring Pharmaceuticals Inc.
$128
RedHill Biopharma Inc.
$101
Intercept Pharmaceuticals, Inc.
$100
Amgen Inc.
$93
Celgene Corporation
$89
Phathom Pharmaceuticals, Inc.
$80
Alfasigma USA, Inc.
$76
Merck Sharp & Dohme Corporation
$66
Nestle HealthCare Nutrition Inc.
$61
Madrigal Pharmaceuticals
$50
EVOKE PHARMA, INC.
$50
Boston Scientific Corporation
$48
AstraZeneca Pharmaceuticals LP
$48
NESTLE HEALTHCARE NUTRITION INC.
$40
Enterra Medical, Inc.
$39
Medtronic, Inc.
$38
Regeneron Healthcare Solutions, Inc.
$35
Ironwood Pharmaceuticals, Inc
$35
Janssen Pharmaceuticals, Inc
$34
Synergy Pharmaceuticals Inc
$31
Daiichi Sankyo Inc.
$28
Organon LLC
$25
Myriad Genetic Laboratories, Inc.
$21
Novo Nordisk Inc
$21
Boehringer Ingelheim Pharmaceuticals, Inc.
$20
AIMMUNE THERAPEUTICS, INC.
$19
Prometheus Laboratories Inc.
$18
Ethicon US, LLC
$17
Ambu Inc.
$14
Shionogi Inc
$14
Axonics Modulation Technologies, Inc.
$13
Allergan, Inc.
$12
Top 3 companies account for 37.6% of all-time payments
Associated products mentioned in payments ›
AVSOLA · Amitiza · Axonics r-SNM System · CAPTIVATOR COLD · CLENPIQ · CREON · Cimzia · Creon · DIFICID · DUPIXENT · Dexilant · ENDOFLIP · ENTYVIO · EOHILIA · Entyvio · GATTEX · GI Genius · GIMOTI · HUMIRA · Humira · IBSRELA · IMFINZI · INJECTAFER · JARDIANCE · LINZESS · Linzess · MAVYRET · MOTEGRITY · MOTOFEN · Mavyret · Mulpleta · OCALIVA · OMVOH · PLENVU · REBYOTA · RELISTOR ORAL · REMICADE · RENFLEXIS · RESMETIROM · RINVOQ · SKYRIZI · STELARA · SUPREP · SUPREP BOWEL PREP · SUTAB · TREMFYA · TRULANCE · Talicia · Trulance · UCERIS TABLETS · VELSIPITY · VIBERZI · VOQUEZNA · Wegovy · XELJANZ · XIFAXAN · XIFAXANIBSD · XIFIXAN · ZENPEP · ZEPATIER · ZEPOSIA · Zelnorm · myRisk · talicia
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Gastroenterologists in nearby ZIP areas
2
County median income
$59,295
Nearest hospital to ZIP centroid (approximate)
CHRISTUS ST MICHAEL HEALTH SYSTEM
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Boehmke is a mixed practice specialist, with above-average Medicare volume (top 1% in TX), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Boehmke experienced with vedolizumab infusion (entyvio)?
Based on Medicare claims data, Dr. Boehmke performed 6,900 vedolizumab infusion (entyvio) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Boehmke receive payments from pharmaceutical companies?
Yes. Dr. Boehmke received a total of $12,960 from 49 companies across 913 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Boehmke's costs compare to other gastroenterologists in Texarkana?
Dr. Boehmke's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Boehmke) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Gastroenterology
Common procedures, typical costs, and what industry payments mean in gastroenterology.
Same specialty & city
Gastroenterologists in Texarkana
Browse gastroenterologists in Texarkana ranked by procedure volume and transparency data.
Highest volume
Top Gastroenterologists in TX
Gastroenterologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Gastroenterologists in TX
Which TX gastroenterologists receive the most from drug and device companies.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc.
By company
Salix Pharmaceuticals, a division of Bausch Health US, LLC Payments to Doctors
See all physicians who received payments from Salix Pharmaceuticals, a division of Bausch Health US, LLC.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology